An exciting new study from the team of Lucintel found thatliquid biopsy market is expected to reach $10.4 billion by 2027 with a CAGR of 17%. There are significant money making opportunities available in thismarket and companies planning to enter this market need to differentiate in order to maximize their return on investment.
Download Brochure of this report by clicking on
https://www.lucintel.com/liquid-biopsy-market.aspx
The liquid biopsymarket is segmented based on product, circulating biomarker, application, clinical application, end use, and region. In this market, circulating tumor DNA (ctDNA)is the largest segment by circulating biomarker, whereas therapy selection is the largest segment by clinical application. Theusage of methylation-specific polymerase chain reaction (MS-PCR) liquid biopsy technology and the emergence of hybrid ctDNA and CTC target selector provides strategic growth path in this market.
Guardant, Bio-Rad Laboratories, Qaigen, MDxHealth, Myriad Genetics, Biocept, Roche, Illumina, and Thermofisher are some of the major players profiled in this 264page report.
Request Sample Pages by clicking on
https://www.lucintel.com/liquid-biopsy-market.aspx
Some of the Key Questions answered in this exclusive report are:
Q.1 What are some of the most promising, high-growth opportunities for the liquid biopsymarket by product (assay kits, instruments, and services), circulating biomarker (circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), cell-free DNA (cfDNA), extracellular vesicles (EVs), and other biomarkers), application (oncology and non-cancer liquid biopsies), clinical application (early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring), end use (reference laboratories, hospitals and physician laboratories, academic and research centers, and other end uses), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2 Which segments will grow at a faster pace and why?
Q.3What are the business risks and threats to the liquid biopsymarket?
Q.4What are some changing demands of customers in the liquid biopsymarket?
Q.5What are the new developments in the liquid biopsymarket? Which companies are leading these developments?
Q.6What strategic initiatives are being implemented by key players for business growth?
Q.7What are some of the competitive products and processes in this liquid biopsyarea and how big of a threat do they pose for loss of market share via product substitution?
Q.8 What M&A activity has occurred in the last 5 years in this liquid biopsymarket?
This unique report from Lucintelwill enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or click on this link [email protected]
About Lucintel
Lucintel, the premier global management consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, growth consulting, M&A, and due diligence services to executives and key decision-makers in a variety of industries. For further information, visit www.lucintel.com.